Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Provention Bio, Inc. - Common Stock (NQ: PRVB )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Provention Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive... 
Via Benzinga
20 Stocks Moving in Thursday's Pre-Market Session
Gainers Alterity Therapeutics Ltd (NASDAQ: ATHE) shares rose 64% to $2.14 in pre-market trading. Alterity Therapeutics recently said it received EU regulatory guidance for ATH434... 
Via Benzinga
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (NYSE: LLY) stood out among big... 
Via Benzinga
Exposures Product Safety
Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type 1 Diabetes
Precigen Inc's (NASDAQ: PGEN) subsidiary Precigen ActoBio announced topline results from the Phase 1b/2a study evaluating AG019 ActoBiotics to treat recent-... 
Via Benzinga
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
NASDAQ:PRVB Investor Notice: Lawsuit Alleges Securities Laws Violations by Provention Bio, Inc.
San Diego, CA -- (SBWIRE) -- 06/08/2021 -- An investor, who purchased NASDAQ:PRVB shares, filed a against Provention Bio, Inc. over alleged violations of Federal Securities Laws. 
Via SBWire
Topics Lawsuit
Exposures Financial Legal Product Safety
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Robbins Geller Rudman & Dowd LLP Announces Upcoming Lead Plaintiff Deadline in the Provention Bio, Inc. Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
From Glancy Prongay & Murray LLP
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
From Law Offices of Howard G. Smith
Via Business Wire
PRVB Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Provention Bio, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
SHAREHOLDER ALERT: Robbins LLP Reminds Investors that Provention Bio, Inc. (PRVB) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
44 Biggest Movers From Friday
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) shares jumped 95.7% to close at $7.81 on continued momentum after the company announced it will acquire an Alabama refinery and related... 
Via Benzinga
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors with Losses to Secure Counsel Before Important July 20 Deadline – PRVB
From The Rosen Law Firm, P.A.
Via Business Wire
Why Provention Bio Stock Crashed Today
An FDA advisory committee vote was a lot closer than anticipated. 
Via The Motley Fool
Exposures Product Safety
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Provention Bio, Inc. (PRVB) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Organovo Holdings (NASDAQ:ONVO) stock moved upwards by 28.66% to $10.01 during Friday's regular session. Trading volume for this security as of 12:30 EST is 6.... 
Via Benzinga
38 Stocks Moving In Friday's Mid-Day Session
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) shares surged 48.6% to $5.93 on continued momentum after the company announced it will acquire an Alabama refinery and related... 
Via Benzinga
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Iterum Therapeutics (NASDAQ:ITRM) shares moved upwards by 21.13% to $1.49 during Friday's pre-market session. The company's market cap stands at $266.9... 
Via Benzinga
The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) BioCryst Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
FDA Advisory Committee Votes In Favor Of Approval Of Provention Bio's Diabetes Med
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 10-7 in favor of recommending approval of Provention Bio Inc’s (NASDAQ: PRVB... 
Via Benzinga
Exposures Product Safety
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Provention Bio, Inc. (PRVB) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.